![Nach erteilter Marktzulassung für EBVALLO® (Tabelecleucel) durch die Europäische Kommission: Pierre Fabre vermarktet und vertreibt erste zugelassene allogene T-Zell-Immuntherapie in Europa Nach erteilter Marktzulassung für EBVALLO® (Tabelecleucel) durch die Europäische Kommission: Pierre Fabre vermarktet und vertreibt erste zugelassene allogene T-Zell-Immuntherapie in Europa](https://mma.prnewswire.com/media/1970795/Pierre_Fabre_Atara_Logo.jpg?p=facebook)
Nach erteilter Marktzulassung für EBVALLO® (Tabelecleucel) durch die Europäische Kommission: Pierre Fabre vermarktet und vertreibt erste zugelassene allogene T-Zell-Immuntherapie in Europa
![PIERRE FABRE GROUP Accelerating online growth with a global e-Retail upskilling programme - Artefact PIERRE FABRE GROUP Accelerating online growth with a global e-Retail upskilling programme - Artefact](https://www.artefact.com//wp-content/uploads/2021/06/pierre-fabre-laboratory.jpeg)
PIERRE FABRE GROUP Accelerating online growth with a global e-Retail upskilling programme - Artefact
Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets
![Atara Biotherapeutics' Ebvallo® (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD | | victoriaadvocate.com Atara Biotherapeutics' Ebvallo® (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD | | victoriaadvocate.com](https://bloximages.newyork1.vip.townnews.com/victoriaadvocate.com/content/tncms/assets/v3/editorial/a/bd/abd798ca-3ba6-523c-afb7-4e8b90345149/63a055db2d3d5.image.jpg?resize=400%2C206)